These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28526302)

  • 1. An Important Role of VEGF-C in Promoting Lymphedema Development.
    Gousopoulos E; Proulx ST; Bachmann SB; Dieterich LC; Scholl J; Karaman S; Bianchi R; Detmar M
    J Invest Dermatol; 2017 Sep; 137(9):1995-2004. PubMed ID: 28526302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.
    Visuri MT; Honkonen KM; Hartiala P; Tervala TV; Halonen PJ; Junkkari H; Knuutinen N; Ylä-Herttuala S; Alitalo KK; Saarikko AM
    Angiogenesis; 2015 Jul; 18(3):313-26. PubMed ID: 26018927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary lymphedema in the mouse tail: Lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9.
    Rutkowski JM; Moya M; Johannes J; Goldman J; Swartz MA
    Microvasc Res; 2006 Nov; 72(3):161-71. PubMed ID: 16876204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased interstitial protein because of impaired lymph drainage does not induce fibrosis and inflammation in lymphedema.
    Markhus CE; Karlsen TV; Wagner M; Svendsen ØS; Tenstad O; Alitalo K; Wiig H
    Arterioscler Thromb Vasc Biol; 2013 Feb; 33(2):266-74. PubMed ID: 23288156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of inflammation and fibrosis by macrophages in lymphedema.
    Ghanta S; Cuzzone DA; Torrisi JS; Albano NJ; Joseph WJ; Savetsky IL; Gardenier JC; Chang D; Zampell JC; Mehrara BJ
    Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1065-77. PubMed ID: 25724493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
    Lohela M; Heloterä H; Haiko P; Dumont DJ; Alitalo K
    Am J Pathol; 2008 Dec; 173(6):1891-901. PubMed ID: 18988807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphangiogenesis Facilitates Initial Lymph Formation and Enhances the Dendritic Cell Mobilizing Chemokine CCL21 Without Affecting Migration.
    Karlsen TV; Reikvam T; Tofteberg A; Nikpey E; Skogstrand T; Wagner M; Tenstad O; Wiig H
    Arterioscler Thromb Vasc Biol; 2017 Nov; 37(11):2128-2135. PubMed ID: 28935759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1.
    Jha SK; Rauniyar K; Karpanen T; Leppänen VM; Brouillard P; Vikkula M; Alitalo K; Jeltsch M
    Sci Rep; 2017 Jul; 7(1):4916. PubMed ID: 28687807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracorporeal shock wave therapy ameliorates secondary lymphedema by promoting lymphangiogenesis.
    Kubo M; Li TS; Kamota T; Ohshima M; Shirasawa B; Hamano K
    J Vasc Surg; 2010 Aug; 52(2):429-34. PubMed ID: 20670777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptor deficiency worsens inflammation and lymphedema after lymphatic injury.
    Zampell JC; Elhadad S; Avraham T; Weitman E; Aschen S; Yan A; Mehrara BJ
    Am J Physiol Cell Physiol; 2012 Feb; 302(4):C709-19. PubMed ID: 22049214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphangiogenesis-independent resolution of experimental edema.
    Ongstad EL; Bouta EM; Roberts JE; Uzarski JS; Gibbs SE; Sabel MS; Cimmino VM; Roberts MA; Goldman J
    Am J Physiol Heart Circ Physiol; 2010 Jul; 299(1):H46-54. PubMed ID: 20207821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: immunohistochemical and molecular characterization.
    Jin DP; An A; Liu J; Nakamura K; Rockson SG
    Lymphat Res Biol; 2009; 7(1):47-57. PubMed ID: 19302023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth factor therapy and lymph node graft for lymphedema.
    Tervala TV; Hartiala P; Tammela T; Visuri MT; Ylä-Herttuala S; Alitalo K; Saarikko AM
    J Surg Res; 2015 Jun; 196(1):200-7. PubMed ID: 25777822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The VEGF-C/VEGFR3 signaling pathway contributes to resolving chronic skin inflammation by activating lymphatic vessel function.
    Hagura A; Asai J; Maruyama K; Takenaka H; Kinoshita S; Katoh N
    J Dermatol Sci; 2014 Feb; 73(2):135-41. PubMed ID: 24252749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
    Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
    Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targeting of lymphatics for therapy.
    Stacker SA; Hughes RA; Achen MG
    Curr Pharm Des; 2004; 10(1):65-74. PubMed ID: 14754406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular Endothelial Growth Factor C (VEGF-C) Sensitizes Lymphatic Endothelial Cells to Oxidative-Stress-Induced Apoptosis through DNA Damage and Mitochondrial Dysfunction: Implications for Lymphedema.
    Hossain L; Gomes KP; Yang X; Liu E; Du Toit J; von der Weid PY; Gibson SB
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adipose-derived stem cell transplantation for therapeutic lymphangiogenesis in a mouse secondary lymphedema model.
    Yoshida S; Hamuy R; Hamada Y; Yoshimoto H; Hirano A; Akita S
    Regen Med; 2015; 10(5):549-62. PubMed ID: 26237700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.
    Karkkainen MJ; Haiko P; Sainio K; Partanen J; Taipale J; Petrova TV; Jeltsch M; Jackson DG; Talikka M; Rauvala H; Betsholtz C; Alitalo K
    Nat Immunol; 2004 Jan; 5(1):74-80. PubMed ID: 14634646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracorporeal shock wave therapy combined with vascular endothelial growth factor-C hydrogel for lymphangiogenesis.
    Kim IG; Lee JY; Lee DS; Kwon JY; Hwang JH
    J Vasc Res; 2013; 50(2):124-33. PubMed ID: 23208012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.